Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients
Prospective, Randomized, Placebo Controlled Trial of the Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients
Sponsor: Cystic Fibrosis Foundation
Terminated
Terminated for the safety of cystic fibrosis clinical trial subjects due to Covid-19.
Other terminated trials from Cystic Fibrosis Foundation
Other Cystic Fibrosis trials with similar outcome
This PHASE2 trial investigates Cystic Fibrosis and is currently terminated or withdrawn. Cystic Fibrosis Foundation leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2021 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Sep 2019 — Mar 2020 [monthly]
Recruiting PHASE2
-
Jan 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Mar 2017 — May 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Mar 2017 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cystic Fibrosis Foundation
- Mallinckrodt
- Novoteris, LLC
For direct contact, visit the study record on ClinicalTrials.gov .